Five Innovative TCM Drug Approvals in 2026: What the Labels Mean

In short

Five registration announcements between June and October 2026 concern Class 1.1 traditional Chinese medicine (TCM) products. They address particular insomnia, knee osteoarthritis, childhood constipation, depression and cough indications. The approved wording matters: a broad symptom name is not the whole indication, and a TCM pattern is not something to self-diagnose from an article.

An approval allows a specified product to be marketed under its authorised conditions. It does not prove that it is better than existing treatment, available at every hospital, approved in another country or suitable for you.

The five products and their limits

The dates below are the months of the cited public announcements; approval dates and commercial availability must be checked separately. The use descriptions are abbreviated; the approved product information and a clinician's assessment govern prescribing.

Product and source	Announcement / company	Indication context
Zaoren Ningxin Dripping Pills（枣仁宁心滴丸）	2026-06 · Tasly	Insomnia with the specified heart–liver blood-deficiency TCM pattern; not all sleep problems.
Jiaoqi Zhitong Gel Patch（椒七止痛凝胶贴膏）	2026-07 · Jiudian	Knee osteoarthritis with the cold-congealing and blood-stasis pattern; an external preparation.
Xiao'er Tongbian Granules（小儿通便颗粒）	2026-08 · Jumpcan	Childhood constipation with the food-accumulation pattern; age and other label conditions still require review.
Xingpi Jieyu Tablets（醒脾解郁片）	2026-09 · Tongjitang	Mild-to-moderate depression with the symptoms and TCM presentation specified in the approval.
Zihua Wenfei Zhisou Granules（紫花温肺止嗽颗粒）	2026-10 · Yuekang	Cough with the wind-cold lingering-in-the-lung pattern; not a general treatment for every cough.

Registration category is not an efficacy ranking

Class 1.1 belongs to the innovative TCM registration pathway. Class 3.1 concerns compound preparations managed under the catalogue of classical formulas. These categories have different evidence and submission requirements; the NMPA expressly says that a registration category does not rank development quality or therapeutic efficacy. Do not treat “innovative” as “better for this patient”, or assume every category follows an identical clinical-trial route.

The label may combine a biomedical condition with a TCM pattern. This is not a reason to ignore a conventional diagnosis or stop established care. The prescriber needs the complete indication, contraindications and relevant clinical information.

What an international patient should check

1. Ask the clinician which diagnosis and label conditions apply, and what alternatives exist.
2. Bring a complete list of medicines, supplements, allergies and previous reactions so the clinician can assess interactions and risks.
3. Confirm the exact product, registration details, local stock, prescription requirements and follow-up arrangements with the provider.
4. Before taking medicine home, check destination-country authorisation, customs and personal-import requirements. Chinese approval is not an overseas licence.

Registered manufactured products, hospital preparations, individual herbal prescriptions and supplements are not interchangeable regulatory categories. PriumCare does not sell, source or recommend medicines. It can help prepare records and coordinate a consultation; prescribing remains the clinician's responsibility.

Frequently asked questions

What does Class 1.1 tell me?

It identifies an innovative TCM registration category. It is not a patient-specific recommendation or a comparative effectiveness score. Read the approved indication rather than relying on the category alone.

Why do the descriptions mention TCM patterns?

Those qualifiers are part of the approved use. For example, the childhood-constipation announcement specifies a food-accumulation pattern. A clinician must assess the condition and the label; having the symptom alone does not establish suitability.

Can I buy these medicines outside China?

Do not infer overseas approval, stock or lawful import from Chinese registration. Check the regulator and dispensing rules in the relevant country. This page does not establish the overseas marketing status of each product.

Does approval mean that the medicine is safe for everyone?

No. Benefits, adverse effects, interactions and uncertainties must be discussed for the individual. A registration announcement is not a substitute for the current product information or follow-up plan; do not change prescribed treatment on the basis of this article.

Sources and editorial update

The five product links above lead to the regulator's notice or the manufacturer's registration disclosure, including exchange-filed announcements. NMPA registration-category rules explain why categories must not be treated as efficacy rankings. Manufacturer disclosures establish what was announced; they do not independently establish comparative clinical superiority.

Editorial source check: 25 October 2026; not a clinical review. This update adds the missing product table, keeps indication qualifiers and separates authorisation from access. The previous claims of an unprecedented approval pace and universal overseas unavailability are not carried forward.

Next step

Ask about preparing records for a TCM consultation. Confirm consultation scope and charges before booking; a coordination enquiry is not a prescription.

Keep reading

• Beijing TCM medical tourism programmes
• How PriumCare checks doctors and hospitals